Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Rhea-AI Summary

Eledon Pharmaceuticals (Nasdaq: ELDN) announced an oral presentation of topline results from the Phase 2 BESTOW trial of tegoprubart for prevention of rejection in kidney transplantation at ASN Kidney Week 2025 in Houston on November 6, 2025.

The presentation by Andrew Adams, M.D., Ph.D. is scheduled for 5:30–5:42 p.m. CT in Grand Ballroom C. A conference call to discuss the results will be held on November 7, 2025 at 8:00 a.m. ET with a live webcast on the company investor site; the webcast will be archived after the call.

Insights

Clinical/Transplant Trial Analyst

Late-breaking Phase 2 topline results for tegoprubart will be presented at Kidney Week; a conference call follows on November 7, 2025.

The presentation announces topline data from the Phase 2 BESTOW trial evaluating tegoprubart for prevention of rejection in kidney transplantation. An oral slot in the "Late-Breaking Research Orals" session and a follow-up conference call create a clear pathway for the data to reach clinicians, trialists, and market participants quickly.

Caveats include that no efficacy or safety figures are disclosed here; the announcement only confirms presentation logistics and a webcast. Key items to watch are the oral presentation on November 6, 2025 (5:30 p.m. CT) and the company call/webcast on November 7, 2025 at 8:00 a.m. ET, where topline metrics and safety signals should be provided for evaluation within an immediate post‑presentation window.

Conference call and webcast to discuss results to be held on November 7, 2025 at 8:00 a.m. ET

IRVINE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the American Society of Nephrology’s upcoming Kidney Week 2025 Annual Meeting taking place in Houston, TX, from November 5-8, 2025. The oral presentation will highlight topline results from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation.

Details of the oral presentation are below:

Title:  Efficacy and Safety of Tegoprubart for the Prevention of Rejection in Kidney Transplantation: Results from the Phase 2 BESTOW Trial
Presenter:  Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota; Executive Medical Director, Solid Organ Transplant Service Line, M Health Fairview
Abstract Publication Number: TH-OR089 
Session Title:  Late-Breaking Research Orals - 1
Session Date and Time: November 6, 2025, from 4:30 p.m. to 6:00 p.m. CT
Session Room: Grand Ballroom C (Convention Center)
Presentation Time: 5:30 p.m. to 5:42 p.m. CT

Conference Call

Eledon will hold a conference call on November 7, 2025 at 8:00 a.m. Eastern Time to discuss the Phase 2 BESTOW trial results presented at Kidney Week. The dial-in numbers are 1-800-717-1738 for domestic callers and 1-646-307-1865 for international callers. The conference ID is 92427. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.eledon.com. The webcast will be archived on the website following the completion of the call.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com

Source: Eledon Pharmaceuticals

FAQ

When will Eledon (ELDN) present BESTOW Phase 2 topline results at ASN Kidney Week 2025?

The oral presentation is on November 6, 2025, with the ESG session time listed from 5:30–5:42 p.m. CT in Grand Ballroom C.

Who is presenting Eledon’s (ELDN) Phase 2 BESTOW trial results on November 6, 2025?

The presenter is Andrew Adams, M.D., Ph.D., Professor of Surgery and Executive Medical Director, Solid Organ Transplant Service Line.

When and how can investors hear Eledon (ELDN) discuss BESTOW results live?

Eledon will host a conference call on November 7, 2025 at 8:00 a.m. ET with a live webcast available on the company’s Investor Relations website; the webcast will be archived afterward.

What dial-in details are provided for the Eledon (ELDN) conference call on November 7, 2025?

Domestic dial-in is 1-800-717-1738, international dial-in is 1-646-307-1865, and the conference ID is 92427.

Where will the BESTOW presentation abstract appear at ASN Kidney Week 2025?

The abstract publication number is TH-OR089 in the Late-Breaking Research Orals - 1 session.